Alzheimer's disease (AD) is a progressive neurodegenerative disorder. Findings from the literature, and preliminary data reported in this application, suggest lipid measures, including brain-derived cholesterol species and lipid peroxidation products, may produce unique, readily detectable signatures in the blood of AD patients. These signatures may be indicators of AD-associated neurodegeneration, producing candidate biomarkers of disease progression. Thus far no longitudinal studies have been conducted in this area. This is important because the rate of change or accumulation of a biomarker may be a better indicator of disease progression than a single value or range at one time point. Such a biomarker could be used as a surrogate or secondary outcome measure in clinical trials of emerging therapies for AD, or may be a prognostic indicator of disease progression. A blood-based biomarker would be superior to CSF-based or brain imaging biomarkers with regard to cost, invasiveness and feasibility. We propose a proof-of-concept study to explore the clinical utility of 24S-hydroxycholesterol (24S-OHC), 24S-OHC/27- hydroxycholesterol ratio, 24S-OHC/cholesterol ratio and F2a-isoprostanes as blood-based biomarkers of AD-associated neurodegeneration using a longitudinal study design. We will recruit well-characterized patients with mild probable AD (pAD), amnestic mild cognitive impairment (MCI), and age-matched cognitively normal controls, 30 per group, from the Johns Hopkins Alzheimer Disease Research Center (JHADRC). These individuals are already followed annually as part of the Center's Clinical Core. For the proposed study, individuals will be asked to provide fasting blood samples at three time points, during two regularly scheduled annual visits, and during a six month visit in between, at which point they will undergo additional cognitive testing. Additional years of follow-up beyond the duration of this study will be available through the JHADRC. Analyses will (1) Estimate the variability of plasma levels of each biomarker both within and between individuals at baseline, 6 months and 1 year and determine factors that effect this variability; (2) Compare the cross-sectional and longitudinal variations and trajectories in biomarkers for the three groups of individuals with varying AD pathology; (3) Determine whether baseline biomarker levels predict one-year cognitive decline; (4) Assess change in biomarker levels as subsequent predictors of cognition decline; and (5) Determine whether the sum of the biomarker levels over one year are related to intra-individual cognitive change. This R21 application proposes a proof-of-concept study to explore the clinical utility of blood- based lipid biomarkers, including 24S-hydroxycholesterol and F2a-isoprostanes, as indicators of Alzheimer's disease (AD)-associated neurodegeneration. Such a biomarker of neurodegeneration would have several applications, including prognosis after the onset of dementia, prognosis of conversion from mild cognitive impairment to dementia, or prognosis in the preclinical phases of the disease. A major application would be as a surrogate or secondary outcome measure in clinical trials of emerging therapies for AD. ? ? ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AG028754-02
Application #
7491658
Study Section
Special Emphasis Panel (ZRG1-HOP-V (02))
Program Officer
Hsiao, John
Project Start
2007-09-01
Project End
2010-08-31
Budget Start
2008-09-01
Budget End
2010-08-31
Support Year
2
Fiscal Year
2008
Total Cost
$204,918
Indirect Cost
Name
Johns Hopkins University
Department
Psychiatry
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Parker, Daniel C; Mielke, Michelle M; Yu, Qilu et al. (2013) Plasma neopterin level as a marker of peripheral immune activation in amnestic mild cognitive impairment and Alzheimer's disease. Int J Geriatr Psychiatry 28:149-54
Oishi, Kenichi; Akhter, Kazi; Mielke, Michelle et al. (2011) Multi-modal MRI analysis with disease-specific spatial filtering: initial testing to predict mild cognitive impairment patients who convert to Alzheimer's disease. Front Neurol 2:54
Gracia-Garcia, Patricia; Rao, Vani; Haughey, Norman J et al. (2011) Elevated plasma ceramides in depression. J Neuropsychiatry Clin Neurosci 23:215-8
Mielke, Michelle M; Haughey, Norman J; Bandaru, Veera Venkata Ratnam et al. (2011) Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J Alzheimers Dis 27:259-69
Mielke, Michelle M; Lyketsos, Constantine G (2010) Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromolecular Med 12:331-40
Oh, Esther S; Mielke, Michelle M; Rosenberg, Paul B et al. (2010) Comparison of conventional ELISA with electrochemiluminescence technology for detection of amyloid-* in plasma. J Alzheimers Dis 21:769-73
Mielke, M M; Zandi, P P; Shao, H et al. (2010) The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 75:1888-95
Mielke, Michelle M; Haughey, Norman J; Bandaru, Veera Venkata Ratnam et al. (2010) Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 6:378-85
Ewers, Michael; Mielke, Michelle M; Hampel, Harald (2010) Blood-based biomarkers of microvascular pathology in Alzheimer's disease. Exp Gerontol 45:75-9
Lyketsos, Constantine G; Szekely, Christine A; Mielke, Michelle M et al. (2008) Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr 20:871-89